The insight gained from ADAPT study [18], combined with that from previously published studies of other automated insulin delivery systems, suggests that AHCL should be considered at the early stages in the type 1 diabetes treatment pathway, in order to have reduced risk of long-term complications [18]. The gene discussed is INS; the disease is type 1 diabetes mellitus.